IL42787A - Compositions for promotion of protein synthesis and suppression of urea formation in the body utilizing alpha-hydroxy acid analogs of amino acids - Google Patents

Compositions for promotion of protein synthesis and suppression of urea formation in the body utilizing alpha-hydroxy acid analogs of amino acids

Info

Publication number: IL42787A
Authority: IL; Israel
Prior art keywords: parts; sodium; composition; hydroxy; calcium salt
Prior art date: 1973-04-30

Application number

IL42787A

Other languages

English (en)

Other versions

IL42787A0 (en

Original Assignee

Mac Kenzie Walser

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1973-04-30

Filing date

1973-07-19

Publication date

1977-05-31

1973-07-19 Application filed by Mac Kenzie Walser filed Critical Mac Kenzie Walser

1973-10-25 Publication of IL42787A0 publication Critical patent/IL42787A0/xx

1977-05-31 Publication of IL42787A publication Critical patent/IL42787A/en

Links

239000000203 mixture Substances 0.000 title claims description 18
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 title claims description 9
239000004202 carbamide Substances 0.000 title claims description 9
230000015572 biosynthetic process Effects 0.000 title claims description 6
238000001243 protein synthesis Methods 0.000 title claims description 5
230000014616 translation Effects 0.000 title claims description 5
229940061720 alpha hydroxy acid Drugs 0.000 title claims 2
150000001280 alpha hydroxy acids Chemical class 0.000 title claims 2
150000001413 amino acids Chemical class 0.000 title description 4
230000001629 suppression Effects 0.000 title description 3
238000011282 treatment Methods 0.000 claims description 6
125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 4
230000001737 promoting effect Effects 0.000 claims description 2
159000000007 calcium salts Chemical class 0.000 claims 10
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 9
239000011734 sodium Substances 0.000 claims 9
229910052708 sodium Inorganic materials 0.000 claims 9
QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims 6
125000002887 hydroxy group Chemical group [H]O* 0.000 claims 3
229960004799 tryptophan Drugs 0.000 claims 3
RILPIWOPNGRASR-RFZPGFLSSA-N (2R,3R)-2-hydroxy-3-methylpentanoic acid Chemical compound CC[C@@H](C)[C@@H](O)C(O)=O RILPIWOPNGRASR-RFZPGFLSSA-N 0.000 claims 2
KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims 2
239000002253 acid Substances 0.000 claims 2
238000007911 parenteral administration Methods 0.000 claims 2
159000000000 sodium salts Chemical class 0.000 claims 2
QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 claims 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims 1
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 1
229930194542 Keto Natural products 0.000 claims 1
235000019766 L-Lysine Nutrition 0.000 claims 1
ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 claims 1
229930064664 L-arginine Natural products 0.000 claims 1
235000014852 L-arginine Nutrition 0.000 claims 1
AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims 1
COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims 1
239000004472 Lysine Substances 0.000 claims 1
239000011575 calcium Substances 0.000 claims 1
229910052791 calcium Inorganic materials 0.000 claims 1
229960000310 isoleucine Drugs 0.000 claims 1
AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims 1
125000000468 ketone group Chemical group 0.000 claims 1
208000017169 kidney disease Diseases 0.000 claims 1
208000019423 liver disease Diseases 0.000 claims 1
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims 1
150000002994 phenylalanines Chemical class 0.000 claims 1
150000003839 salts Chemical class 0.000 claims 1
230000015556 catabolic process Effects 0.000 description 3
102000015781 Dietary Proteins Human genes 0.000 description 2
108010010256 Dietary Proteins Proteins 0.000 description 2
235000021245 dietary protein Nutrition 0.000 description 2
230000002440 hepatic effect Effects 0.000 description 2
235000018102 proteins Nutrition 0.000 description 2
102000004169 proteins and genes Human genes 0.000 description 2
108090000623 proteins and genes Proteins 0.000 description 2
206010020575 Hyperammonaemia Diseases 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
239000000470 constituent Substances 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
230000000694 effects Effects 0.000 description 1
230000037406 food intake Effects 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
239000002243 precursor Substances 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Coloring Foods And Improving Nutritive Qualities (AREA)
Indole Compounds (AREA)

IL42787A 1973-04-30 1973-07-19 Compositions for promotion of protein synthesis and suppression of urea formation in the body utilizing alpha-hydroxy acid analogs of amino acids IL42787A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US35532673A	1973-04-30	1973-04-30

Publications (2)

Publication Number	Publication Date
IL42787A0 IL42787A0 (en)	1973-10-25
IL42787A true IL42787A (en)	1977-05-31

Family

ID=23397057

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IL42787A IL42787A (en)	1973-04-30	1973-07-19	Compositions for promotion of protein synthesis and suppression of urea formation in the body utilizing alpha-hydroxy acid analogs of amino acids

Country Status (7)

Country	Link
JP (1)	JPS49135966A (fr)
BE (1)	BE803567A (fr)
CA (1)	CA1023664A (fr)
DE (1)	DE2335216A1 (fr)
FR (1)	FR2226994B1 (fr)
GB (1)	GB1442154A (fr)
IL (1)	IL42787A (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3950529A (en) *	1975-02-03	1976-04-13	Massachusetts General Hospital	Amino acid formulations for patients with liver disease and method of using same
DE2530246A1 (de) *	1975-07-07	1977-01-13	Fresenius Chem Pharm Ind	L-aminosaeuregemische fuer parenterale oder orale anwendung
DE2531299A1 (de) *	1975-07-12	1977-01-13	Fresenius Chem Pharm Ind	L-amino- und hydroxy- und/oder ketosaeuren enthaltende gemische fuer parenterale oder orale anwendung
DE2636828A1 (de) *	1976-08-16	1978-02-23	Fresenius Chem Pharm Ind	L-amonosaeurengemische fuer die behandlung von leberinsuffizienz sowie die herstellung derartiger gemische
US4296127A (en) *	1979-04-18	1981-10-20	The Johns Hopkins University	Mixed salts of essential or semi-essential amino acids and nitrogen-free analogs thereof
US4752619A (en) *	1985-12-23	1988-06-21	The Johns Hopkins University	Nutritional supplement for treatment of uremia
SE8803143L (sv) *	1988-09-07	1990-03-08	Kabivitrum Ab	Alternativa energisubstrat
DE3943424A1 (de) *	1989-12-30	1991-07-04	Nephro Medica Pharma	Infusions- und injektionsloesung zur intravenoesen verabreichung
JP2014512372A (ja) *	2011-04-18	2014-05-22	ネステクソシエテアノニム	α−ＨＩＣＡ及びエイコサペンタエン酸を含有する栄養組成物

1973
- 1973-07-05 GB GB3212173A patent/GB1442154A/en not_active Expired
- 1973-07-11 DE DE19732335216 patent/DE2335216A1/de active Pending
- 1973-07-12 CA CA176,338A patent/CA1023664A/fr not_active Expired
- 1973-07-19 IL IL42787A patent/IL42787A/en unknown
- 1973-08-03 FR FR7328498A patent/FR2226994B1/fr not_active Expired
- 1973-08-14 BE BE2052988A patent/BE803567A/fr not_active IP Right Cessation
- 1973-10-11 JP JP48114328A patent/JPS49135966A/ja active Pending

Also Published As

Publication number	Publication date
FR2226994A1 (fr)	1974-11-22
GB1442154A (en)	1976-07-07
BE803567A (fr)	1973-12-03
IL42787A0 (en)	1973-10-25
FR2226994B1 (fr)	1977-08-12
JPS49135966A (fr)	1974-12-27
AU6015373A (en)	1975-03-13
DE2335216A1 (de)	1974-11-21
CA1023664A (fr)	1978-01-03

Similar Documents

Publication	Publication Date	Title
US4100161A (en)	1978-07-11	Promotion of protein synthesis and suppression of urea formation in the body by keto analogs of essential amino acids
US4100160A (en)	1978-07-11	Therapeutic compositions comprising alpha-hydroxy analogs of essential amino acids and their administration to humans for promotion of protein synthesis and suppression of urea formation
EP1062879B1 (fr)	2003-08-27	Solution aqueuse pour nutrition parentérale
KR840003414A (ko)	1984-09-08	3-히드록시부탄산 또는 이 산으로부터 유도된 염을 함유하는 약학적 조성물과, 의약품으로 사용할 수 있는 3-히드록시부탄산으로부터 유도된 화합물
US5863906A (en)	1999-01-26	Composition based on amino acids intended for the treatment of sepsis or of an attack bringing about an inflammatory reaction, in animals and man
JPH09512552A (ja)	1997-12-16	腎疾患および不全の治療方法ならびに組成物
AU627041B2 (en)	1992-08-13	Improved nutritional formulation for the treatment of renal disease
IL42787A (en)	1977-05-31	Compositions for promotion of protein synthesis and suppression of urea formation in the body utilizing alpha-hydroxy acid analogs of amino acids
OKITA et al.	1985	Nutritional treatment of liver cirrhosis by branched-chain amino acid-enriched nutrient mixture
IL42726A (en)	1977-10-31	Composition for promotion of protein synthesis and suppression of urea formation in the body
AU690533B2 (en)	1998-04-30	Protein preparation for the prevention and therapy of periodontitis or other bacterial pathologies of the oral cavity
FI88581B (fi)	1993-02-26	Foerfarande foer framstaellning av en naeringstillsats foer behandling av uremi
Connors et al.	1960	The pharmacology and tumour growth inhibitory activity of 1-aminocyclopentane-1-carboxylic acid and related compounds
WO2003000173A3 (fr)	2004-03-04	Utilisation d'acides gras a chaine ramifiee et derives de ces acides gras pour le traitement de la douleur
Gershoff et al.	1962	Effect of vitamin B6 and magnesium on renal deposition of calcium oxalate induced by ethylene glycol administration.
McLean et al.	1989	Effect of D-or L-methionine and cysteine on the growth inhibitory effects of feeding 1% paracetamol to rats
JPH04312527A (ja)	1992-11-04	肝不全および肝臓疾患の治療方法
DE2712777A1 (de)	1977-10-20	Arzneimittel zur foerderung der proteinsynthese und zur konservierung des stickstoffs im koerper
Martín Calero et al.	1997	Protective effect of L‐arginine against ibuprofen‐induced gastric injury in rats
KR20070086007A (ko)	2007-08-27	당뇨병의 치료를 위한 의약 조성물
JPH0374327A (ja)	1991-03-28	アルコール代謝促進剤
KR920006904B1 (ko)	1992-08-22	디메르캅토 숙신산(dmsa)을 활성성분으로 한 약제학적 조성물
US20070141121A1 (en)	2007-06-21	Method of treating kidney disease
JPH02131421A (ja)	1990-05-21	肝障害抑制剤
KURAHASHI et al.	1976	Mechanism of thyroid-induced creatinuria in rat, with special reference to creatine synthesis in liver and creatine loss from skeletal muscle